Polymeric delivery systems for nucleic acid therapeutics: Approaching the clinic
Полимерные системы доставки нуклеиновых кислот для терапии: на пути к клиническому применению
2021-01-14
SCID: 54.1/kzxbb3wd
Discuss with AI
gene therapynon-viral carriersnucleic acid therapeuticspolymeric delivery systemspolyplexes
Figures from the paper
Abstract (AI)
Gene therapy using nucleic acids has many clinical applications for the treatment of diseases with a genetic origin as well as for the development of innovative vaccine formulations. Since nucleic acids in their free form are rapidly degraded by nucleases present in extracellular matrices, have poor pharmacokinetics and hardly pass cellular membranes, carrier systems are required. Suitable carriers that protect the nucleic acid payload against enzymatic attack, prolong circulation time after systemic administration and assist in cellular binding and internalization are needed to develop nucleic acid based drug products. Viral vectors have been investigated and are also clinically used as delivery vehicles. However, some major drawbacks are associated with their use. Therefore there has been substantial attention on the use of non-viral carrier systems based on cationic lipids and polymers. This review focuses on the properties of polymer-based nucleic acid formulations, also referred as polyplexes. Different polymeric systems are summarized, and the cellular barriers polyplexes encounter and ways to tackle these are discussed. Finally attention is given to the clinical status of non-viral nucleic acid formulations.
Key Findings
1
Effective delivery systems must protect nucleic acid payloads, extend systemic circulation, and promote cellular binding and internalization.
2
Free nucleic acids require carrier systems because they are rapidly degraded by extracellular nucleases, exhibit poor pharmacokinetics, and inefficiently cross cellular membranes.
3
Polymeric nucleic acid formulations, or polyplexes, are reviewed with emphasis on their properties, cellular barriers, and strategies to overcome those barriers.
4
The clinical status of non-viral nucleic acid formulations is assessed, highlighting progress toward clinical application.
5
Viral vectors are clinically used but have important drawbacks, motivating development of non-viral carriers based on cationic lipids and polymers.
Research Object
polymer-based nucleic acid formulations (polyplexes) for therapeutic delivery
Research Subject
their properties, cellular barriers, strategies to overcome these barriers, and clinical status
Publication Details
Publication Date
2021-01-14
Journal
Publisher
ISSN
Cited by
217
Open access PDF
Access Type
Author Information
Download PDF
Subscribe to digest